Addition Therapy, a biotechnology company based in California, has launched with $100 million in initial funding. The company aims to develop one-time therapies for rare and chronic diseases, using its proprietary PRINT platform. This technology is described as an all-RNA, non-viral system that utilizes lipid nanoparticles to deliver therapeutic agents. Non-human primate studies of the platform are scheduled for 2026. No further details about Addition's development pipeline or specific timelines have been disclosed.
The startup has secured investments from several notable organizations, including the Gates Foundation, Abingworth, SR One, and Osage University Partners. In addition to providing financial backing for the launch, the Gates Foundation awarded Addition a grant intended to support research into a single-dose therapy designed to help patients produce antibodies against HIV.
CEO Ron Park will lead Addition Therapy. Park previously worked at Roche as global co-lead of personalized healthcare and was an entrepreneur in residence at Third Rock Ventures. Francine Gregoire will serve as Chief Scientific Officer; she was formerly head of preclinical cardiovascular development at Moderna and held leadership positions at CRISPR Therapeutics and Beam Therapeutics.
Addition also reported ongoing research partnerships with unnamed pharmaceutical companies focused on developing PRINT-based treatments for unspecified rare and chronic diseases.
The emergence of Addition follows similar moves by other startups in the biopharmaceutical sector this year. Crystalys Therapeutics launched in September with $205 million to advance dotinurad—a treatment being tested for gout—while Ollin Biosciences entered the market with $100 million to develop OLN324, an antibody therapy targeting eye diseases.
"Addition Debuts With $100M to Advance One-Time Therapies for Rare, Chronic Diseases"
